CORRECTED-INSIGHT-US benefits manager baulks after Novartis values gene therapy at $4-5 mln By: Reuters: Company News November 23, 2018 at 11:11 AM EST * At $4-5 mln, SMA treatment would be one of industry's costliest Read More >> Related Stocks: Amgen Banco Santander ADR Biogen Idec CVS Health Corp Express Scripts Holding Gilead Sciences Novan Inc Ptc Therapeutics Regeneron Pharmaceuticals Rogers Corp Spark Therap Vertex Pharmaceuticals